Drug intelligence / Profile preview

alpha-galactosidase

Development stage
Unknown
Modality
Recombinant Proteins and Enzymes
Administration
Oral
01

Overview

Alpha-galactosidase is an **enzyme** that hydrolyzes terminal, non-reducing α-D-galactose residues in oligosaccharides, polysaccharides, glycolipids, and glycoproteins, facilitating the digestion of complex carbohydrates and helping to prevent gas, bloating, and digestive discomfort caused by undigested carbohydrates. It is used as an **over-the-counter digestive enzyme supplement**, as well as in enzyme replacement therapy for Fabry disease (where recombinant forms are used). The enzyme is produced industrially from sources like *Aspergillus niger* for dietary supplements. The mechanism of action involves cleavage of α-1,6 and α-1,3 linked galactosides, thereby reducing fermentable carbohydrates that cause gas production in the intestine. In human genetics, deficiency leads to Fabry disease, but in dietary supplements the enzyme is aimed at aiding digestion and reducing flatulence.

Brand names
BeanoGas-X Prevention
Other names
alpha-d-galactosidaseα-galactosidasealpha-galactosidase Aalpha-D-galactoside galactohydrolaseα-GALα-GAL A
02

Targets

Gb3 (Globotriaosylceramide)

Beyond the preview

Go deeper on alpha-galactosidase.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on alpha-galactosidase.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call